• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Suvorexant for the treatment of insomnia in patients with Alzheimer's disease.

作者信息

Hamuro Atsushi, Honda Minoru, Wakaura Yuya

机构信息

1 Department of Psychiatry, Yuzuriha Hospital, Nagasaki, Japan.

2 Department of Nursing, Yuzuriha Hospital, Nagasaki, Japan.

出版信息

Aust N Z J Psychiatry. 2018 Feb;52(2):207-208. doi: 10.1177/0004867417747402. Epub 2017 Dec 14.

DOI:10.1177/0004867417747402
PMID:29237271
Abstract
摘要

相似文献

1
Suvorexant for the treatment of insomnia in patients with Alzheimer's disease.苏沃雷生用于治疗阿尔茨海默病患者的失眠症。
Aust N Z J Psychiatry. 2018 Feb;52(2):207-208. doi: 10.1177/0004867417747402. Epub 2017 Dec 14.
2
Suvorexant: scientifically interesting, utility uncertain.苏沃雷生：具有科学研究价值，但效用尚不确定。
Australas Psychiatry. 2017 Dec;25(6):622-624. doi: 10.1177/1039856217734677. Epub 2017 Oct 10.
3
[Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA(®)), a novel therapeutic agent for insomnia].新型失眠治疗药物双食欲素受体拮抗剂苏沃雷生（BELSOMRA(®)）的临床前及临床研究结果
Nihon Yakurigaku Zasshi. 2016 Jul;148(1):46-56. doi: 10.1254/fpj.148.46.
4
Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.苏沃雷生治疗失眠症患者的疗效：两项为期 3 个月的随机对照临床试验结果。
Biol Psychiatry. 2016 Jan 15;79(2):136-48. doi: 10.1016/j.biopsych.2014.10.003. Epub 2014 Oct 23.
5
Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data.苏沃雷生对失眠患者失眠严重程度指数的影响：汇总 3 期数据的分析。
Sleep Med. 2019 Apr;56:219-223. doi: 10.1016/j.sleep.2018.09.010. Epub 2018 Oct 2.
6
The role of suvorexant in the prevention of delirium during acute hospitalization: A systematic review.苏沃雷生在急性住院期间预防谵妄的作用：系统评价。
J Crit Care. 2020 Oct;59:1-5. doi: 10.1016/j.jcrc.2020.05.006. Epub 2020 May 20.
7
Suvorexant-Induced Delirium.苏沃雷生所致谵妄
Prim Care Companion CNS Disord. 2018 Nov 15;20(6):18l02297. doi: 10.4088/PCC.18l02297.
8
Suvorexant as an orexin antagonist may regulate serum glucose levels in psychiatric patients with insomnia.苏沃雷生作为一种食欲素拮抗剂，可能调节伴有失眠的精神科患者的血清葡萄糖水平。
Psychiatry Clin Neurosci. 2017 Dec;71(12):844. doi: 10.1111/pcn.12608. Epub 2017 Nov 9.
9
Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.苏沃雷生：一种双重食欲素受体拮抗剂治疗失眠的疗效和安全性概况。
Drugs Today (Barc). 2016 Jan;52(1):29-40. doi: 10.1358/dot.2016.52.1.2439940.
10
Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications.食欲素受体拮抗剂治疗失眠及潜在的其他神经精神适应证治疗。
J Sleep Res. 2019 Apr;28(2):e12782. doi: 10.1111/jsr.12782. Epub 2018 Oct 18.

引用本文的文献

1
Protocol and design of the REPOSE study: a double-blinded, randomised, placebo-controlled trial to evaluate the efficacy of suvorexant to improve postoperative sleep and reduce delirium severity in older patients undergoing non-cardiac surgery.REPOSE研究的方案与设计：一项双盲、随机、安慰剂对照试验，旨在评估苏沃雷生改善非心脏手术老年患者术后睡眠及减轻谵妄严重程度的疗效。
BMJ Open. 2025 Mar 13;15(3):e091099. doi: 10.1136/bmjopen-2024-091099.
2
Orexin Receptor Antagonists for the Prevention and Treatment of Alzheimer's Disease and Associated Sleep Disorders.食欲素受体拮抗剂在预防和治疗阿尔茨海默病及相关睡眠障碍中的应用。
Drugs. 2024 Nov;84(11):1365-1378. doi: 10.1007/s40265-024-02096-3. Epub 2024 Oct 4.
3
Integrating lived experience to develop a tailored sleep intervention for people living with dementia and carepartners.
结合生活经验，为痴呆症患者及其护理伙伴制定量身定制的睡眠干预措施。
Dementia (London). 2025 May;24(4):697-719. doi: 10.1177/14713012241282769. Epub 2024 Sep 9.
4
Effects of new hypnotic drugs on cognition: A systematic review and network meta-analysis.新型催眠药物对认知的影响：一项系统评价与网状Meta分析
Sleep Med X. 2023 Nov 19;6:100094. doi: 10.1016/j.sleepx.2023.100094. eCollection 2023 Dec 15.
5
Factors Associated with Prescriptions for an Orexin Receptor Antagonist Among Japanese Patients with Insomnia: Analysis of a Nationwide Japanese Claims Database.日本失眠患者中食欲素受体拮抗剂处方的相关因素：基于日本全国索赔数据库的分析
Drugs Real World Outcomes. 2023 Jun;10(2):271-281. doi: 10.1007/s40801-023-00356-4. Epub 2023 Mar 3.
6
Suvorexant, a Novel Dual Orexin Receptor Antagonist, for the Management of Insomnia.苏沃雷生，一种新型双重食欲素受体拮抗剂，用于治疗失眠。
Health Psychol Res. 2023 Jan 28;10(5):67898. doi: 10.52965/001c.67898. eCollection 2022.
7
Orexin A peptidergic system: comparative sleep behavior, morphology and population in brains between wild type and Alzheimer's disease mice.食欲素 A 肽能系统：野生型和阿尔茨海默病小鼠大脑中的比较睡眠行为、形态和群体。
Brain Struct Funct. 2022 Apr;227(3):1051-1065. doi: 10.1007/s00429-021-02447-w. Epub 2022 Jan 23.
8
Pharmacotherapies for sleep disturbances in dementia.痴呆症睡眠障碍的药物治疗
Cochrane Database Syst Rev. 2020 Nov 15;11(11):CD009178. doi: 10.1002/14651858.CD009178.pub4.
9
Therapy for Insomnia and Circadian Rhythm Disorder in Alzheimer Disease.阿尔茨海默病中失眠和昼夜节律障碍的治疗
Curr Treat Options Neurol. 2020 Feb 5;22(2):4. doi: 10.1007/s11940-020-0612-z.
10
Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders.食欲素受体拮抗剂作为治疗精神障碍的新兴疗法。
Neurosci Bull. 2020 Apr;36(4):432-448. doi: 10.1007/s12264-019-00447-9. Epub 2019 Nov 28.